Endocrinology pp 361-376 | Cite as

Cardiovascular Hormones

  • Willis K. Samson


Although the heart had long been considered merely a muscular pump that performed the physical labor of the circulation, it has been recognized for over five decades that in addition to the contractile ultrastructure, a secretory function was evidenced by the presence of dense-core granules in the myocytes. In the past decade, the endocrine nature of the heart has been established, and the physiology and pathophysiology of the cardiac hormones have been extensively characterized. The myocyte produces both constitutively and in a regulated fashion two members of a class of hormones designated natriuretic peptides on the basis of their abilities to stimulate salt and water excretion by direct renal actions and indirect effects on other tissues, including endocrine organs, responsible for the control of fluid and electrolyte homeostasis. Two members of the natriuretic peptide family, atrial natriuretic peptide (A-type natriuretic peptide, ANP) and brain natriuretic peptide (BNP, actually a misnomer, since although cloned from a brain library, little of this isoform is present in brain) are produced in the heart and released in response to a variety of cues, all typical of plasma volume overload or hyperosmolality. Although numerous biological actions have been characterized, their hallmark effects are to unload the vascular tree via a combination of central nervous system, pituitary, adrenal, vascular, and renal actions (Fig. 1). This results in decreased venous return to the pump as a consequence of increased renal excretion of water and solute, vasorelaxation in certain vascular beds, increased capillary permeability, and decreased cardiac output. The third member of this family of hormones, although exerting many of the same actions as ANP and BNP, is unique in that it is predominantly produced in the vascular endothelium, not the heart, and is thought to act more in a paracrine fashion, regulating primarily vascular tone and growth. Additionally, this hormone, designated C-type natriuretic peptide (CNP), exerts several central nervous system actions that oppose those of ANP and BNP.


Nitric Oxide Natriuretic Peptide Brain Natriuretic Peptide Atrial Natriuretic Peptide Guanylyl Cyclase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Readings

  1. Baldi E, Maggi M, Cameron IT, Dunn MJ, eds. Endothelins in endocrinology: new advances. In: Frontiers in Endocrinology, vol 15. Rome: Ares-Serano Symposia Publications, 1995.Google Scholar
  2. Brandt RR, Wright RS, Redfield MM, Burnett JC. Atrial natriuretic peptide in heart failure. J Am Coll Cardiol 1993; 22: 86A.Google Scholar
  3. Feng CJ, Kang B, Kaye AD, Kadowitz PJ, Nossman BD. L-NAME modulates responses to adrenomedullin in hindquarters vascular bed of the rat. Life Sci 1994; 55: 433.Google Scholar
  4. Haynes WG. Endothelins as regulators of vascular tone in man. Clin Sci 1995; 88: 509.PubMedGoogle Scholar
  5. Hirata Y, Hayakawa H, Suzuki Y, Suzuki E, Ikenouchi H, Kohmoto O, Kimura K, Kitamura K, Eto T, Kangawa K, Matsuo H, Ornata M. Mechanisms of adrenomedullininduced vasodilation in the rat kidney. Hypertension 1995; 25: 790.PubMedCrossRefGoogle Scholar
  6. Inagami T, Naruse M, Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 1995; 57: 171.PubMedCrossRefGoogle Scholar
  7. John SWM, Krege JH, Oliver P, Hagaman J, Hodgin JB, Pang SC, Flynn TG, Marda N, Smithies O. Genetically decreased levels of atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267: 679.PubMedCrossRefGoogle Scholar
  8. Kapas et al. J Biol Chem 1995; 270: 25344.PubMedCrossRefGoogle Scholar
  9. Kitamura K, Kangawa K, Matsuo H, Eto T. Adrenomedullin. Implications for hypertension research. Drugs 1995; 49: 485.PubMedCrossRefGoogle Scholar
  10. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081.PubMedCrossRefGoogle Scholar
  11. Levin ER, Frank HJ. Natriuretic peptides inhibit rat astroglial proliferation: mediation by the C-receptor. Am J Physiol 1991; 261: R453.PubMedGoogle Scholar
  12. Naruse M, Naruse K, Demura H. Recent advances in endothelin research on cardiovascular and endocrine systems. Endocr J 1994; 41: 491.PubMedCrossRefGoogle Scholar
  13. Nazario B, Hu RM, Pedram A, Prins B, Levin ER. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest 1995; 95: 1151.PubMedCrossRefGoogle Scholar
  14. Richards AM. The natriuretic peptides and hypertension. J Int Med 1994; 235: 543.CrossRefGoogle Scholar
  15. Samson WK, Huang FLS, Fulton RJ. C-type natriuretic peptide mediates the hypothalamic actions of the natriuretic peptides to inhibit luteinizing hormone secretion. Endocrinology 1993; 132: 504.PubMedCrossRefGoogle Scholar
  16. Samson WK, Murphy T, Schell DA. A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotropin release. Endocrinology 1995; 136: 2349.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Willis K. Samson

There are no affiliations available

Personalised recommendations